Concepts (126)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Panniculitis | 1 | 2024 | 5 | 0.840 |
Why?
|
| Arthritis | 1 | 2024 | 53 | 0.820 |
Why?
|
| Pancreatitis | 1 | 2024 | 96 | 0.790 |
Why?
|
| Parenteral Nutrition, Home | 3 | 2023 | 3 | 0.760 |
Why?
|
| Short Bowel Syndrome | 2 | 2023 | 6 | 0.570 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2012 | 27 | 0.410 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2004 | 33 | 0.390 |
Why?
|
| Fish Oils | 1 | 2012 | 43 | 0.360 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2012 | 36 | 0.360 |
Why?
|
| Nutritional Requirements | 1 | 2011 | 20 | 0.340 |
Why?
|
| Dietary Fats | 1 | 2012 | 181 | 0.340 |
Why?
|
| Hepatic Encephalopathy | 1 | 2011 | 10 | 0.340 |
Why?
|
| Dietary Proteins | 1 | 2011 | 44 | 0.330 |
Why?
|
| Liver Diseases | 1 | 2012 | 157 | 0.330 |
Why?
|
| Fatty Liver | 1 | 2011 | 115 | 0.320 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 226 | 0.300 |
Why?
|
| Oxidative Stress | 1 | 2011 | 322 | 0.300 |
Why?
|
| Liver | 1 | 2011 | 875 | 0.250 |
Why?
|
| Hypophosphatemia | 1 | 2004 | 7 | 0.210 |
Why?
|
| Inflammation | 1 | 2011 | 1198 | 0.210 |
Why?
|
| Living Donors | 1 | 2004 | 78 | 0.210 |
Why?
|
| Phosphates | 1 | 2004 | 104 | 0.200 |
Why?
|
| Obesity | 1 | 2011 | 1279 | 0.190 |
Why?
|
| Liver Transplantation | 2 | 2007 | 222 | 0.190 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 48 | 0.170 |
Why?
|
| Acclimatization | 1 | 2021 | 11 | 0.170 |
Why?
|
| Altitude | 1 | 2021 | 15 | 0.170 |
Why?
|
| Cross Infection | 1 | 2002 | 170 | 0.170 |
Why?
|
| Alcoholism | 1 | 2024 | 329 | 0.160 |
Why?
|
| HIV Infections | 2 | 2018 | 961 | 0.160 |
Why?
|
| rho-Associated Kinases | 1 | 2019 | 18 | 0.150 |
Why?
|
| Middle Aged | 8 | 2024 | 18491 | 0.150 |
Why?
|
| Neuromuscular Junction | 1 | 2019 | 83 | 0.140 |
Why?
|
| Pyridones | 1 | 2018 | 43 | 0.140 |
Why?
|
| Myosins | 1 | 2019 | 118 | 0.140 |
Why?
|
| Humans | 15 | 2024 | 65826 | 0.130 |
Why?
|
| Anti-HIV Agents | 1 | 2018 | 139 | 0.130 |
Why?
|
| Disease Transmission, Infectious | 1 | 2016 | 20 | 0.120 |
Why?
|
| Anti-Retroviral Agents | 1 | 2016 | 76 | 0.120 |
Why?
|
| Sexual Partners | 1 | 2016 | 76 | 0.120 |
Why?
|
| Zebrafish | 1 | 2019 | 374 | 0.120 |
Why?
|
| Naloxone | 1 | 2014 | 53 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 53 | 0.100 |
Why?
|
| Male | 8 | 2024 | 31398 | 0.100 |
Why?
|
| Narcotic Antagonists | 1 | 2014 | 133 | 0.090 |
Why?
|
| Soybean Oil | 1 | 2012 | 32 | 0.090 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 41 | 0.090 |
Why?
|
| Hepatitis, Chronic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Opiate Substitution Treatment | 1 | 2014 | 226 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 296 | 0.080 |
Why?
|
| Diet, Protein-Restricted | 1 | 2011 | 12 | 0.080 |
Why?
|
| Buprenorphine | 1 | 2014 | 199 | 0.080 |
Why?
|
| HIV-1 | 1 | 2016 | 710 | 0.080 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2011 | 92 | 0.080 |
Why?
|
| Body Weight | 1 | 2011 | 377 | 0.080 |
Why?
|
| Hepatocytes | 1 | 2011 | 226 | 0.080 |
Why?
|
| Sleep | 2 | 2023 | 246 | 0.080 |
Why?
|
| Analgesics, Opioid | 1 | 2014 | 533 | 0.070 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 464 | 0.070 |
Why?
|
| Docosahexaenoic Acids | 1 | 2007 | 31 | 0.070 |
Why?
|
| Arachidonic Acid | 1 | 2007 | 38 | 0.070 |
Why?
|
| Female | 7 | 2023 | 34414 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 809 | 0.060 |
Why?
|
| Postgastrectomy Syndromes | 1 | 2006 | 4 | 0.060 |
Why?
|
| Opioid-Related Disorders | 1 | 2014 | 532 | 0.060 |
Why?
|
| Trace Elements | 1 | 2006 | 22 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2007 | 200 | 0.060 |
Why?
|
| Gastrectomy | 1 | 2006 | 39 | 0.060 |
Why?
|
| Copper | 1 | 2006 | 58 | 0.060 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 184 | 0.060 |
Why?
|
| Anion Exchange Resins | 1 | 2004 | 1 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2004 | 130 | 0.050 |
Why?
|
| Probiotics | 1 | 2004 | 57 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2004 | 165 | 0.050 |
Why?
|
| United States | 2 | 2018 | 8190 | 0.050 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 154 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2018 | 747 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2018 | 5830 | 0.040 |
Why?
|
| Hypocapnia | 1 | 2021 | 3 | 0.040 |
Why?
|
| Adult | 4 | 2023 | 17567 | 0.040 |
Why?
|
| Bicarbonates | 1 | 2021 | 17 | 0.040 |
Why?
|
| Recurrence | 1 | 2002 | 665 | 0.040 |
Why?
|
| Glucose | 1 | 2023 | 478 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2006 | 1336 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1029 | 0.040 |
Why?
|
| Hypoxia | 1 | 2021 | 121 | 0.040 |
Why?
|
| Diketopiperazines | 1 | 2018 | 2 | 0.040 |
Why?
|
| Malawi | 1 | 2018 | 9 | 0.040 |
Why?
|
| South Africa | 1 | 2018 | 15 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 72 | 0.040 |
Why?
|
| Brazil | 1 | 2018 | 104 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2019 | 190 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 120 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 4878 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2018 | 203 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 21 | 0.030 |
Why?
|
| HIV Seropositivity | 1 | 2016 | 81 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 375 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 420 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1267 | 0.030 |
Why?
|
| Bilirubin | 1 | 2014 | 19 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2014 | 46 | 0.030 |
Why?
|
| Thailand | 1 | 2014 | 91 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2790 | 0.030 |
Why?
|
| China | 1 | 2014 | 181 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 2113 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 2496 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5471 | 0.020 |
Why?
|
| alpha-Linolenic Acid | 1 | 2007 | 4 | 0.020 |
Why?
|
| Etanercept | 1 | 2007 | 33 | 0.020 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2007 | 18 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 64 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 6367 | 0.020 |
Why?
|
| Aged | 2 | 2018 | 15141 | 0.020 |
Why?
|
| Phospholipids | 1 | 2007 | 81 | 0.020 |
Why?
|
| Ceruloplasmin | 1 | 2006 | 4 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 171 | 0.020 |
Why?
|
| Ataxia | 1 | 2006 | 21 | 0.020 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 28 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2007 | 324 | 0.010 |
Why?
|
| Triglycerides | 1 | 2007 | 249 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 2006 | 44 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 472 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 236 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 605 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 21489 | 0.010 |
Why?
|